**Supplementary table S1. List of pharmacokinetic parameters and definitions**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters**  | **Drug/Analyte** | **Matrix**  | **Definition/Calculation**  |
| Cmax  | Clopidogrel/SR26334 ASA/SA  | Plasma  | Maximum plasma concentration observed  |
| tmax  | Clopidogrel/SR26334 ASA/SA  | Plasma  | Time to reach Cmax  |
| AUClast  | Clopidogrel/SR26334 ASA/SA  | Plasma  | Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time, tlast  |
| AUC  | Clopidogrel/SR26334 ASA/SA  | Plasma  | Area under the plasma concentration versus time curve extrapolated to infinity according to the following equation: AUC = AUClast + $Clast/λz$ |
| t1/2z  | Clopidogrel/SR26334 ASA/SA  | Plasma  | Terminal half-life associated with the terminal slope (λz) determined according to the following equation: T1/2z = 0.693/λz  where λz is the slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale. Half-life is calculated by taking the regression of at least 3 points.  |

**Supplementary table S2. Pooled point estimate of treatment ratios and SDw as well as the power of each PK parameter of clopidogrel and acetylsalicylic acid**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **PK parameter** | **Pooled point estimate of ratio (Test vs Ref)** | **SDW (90% CI)** | **True ratio for sample size** | **True SDW for sample size** | **Power** | **Statistical method** |
| Clopidogrel | AUClast | 0.99 | 0.344 (0.320; 0.372) | 0.95 | 0.350 | >99% | ABE |
| AUC | 0.98 | 0.335 (0.311; 0.362) | 0.95 | 0.350 | >99% | ABE |
| Cmax | 1.10 | 0.365 (0.340; 0.395) | 1.10 | 0.375 | 94% | ABE |
| Acetylsalicylic acid | AUClast | 1.10 | 0.488 (0.459; 0.522) | 1.10 | 0.490 | >99% | RSABE |
| AUC | 1.10 | 0.416 (0.391; 0.444) | 1.10 | 0.425 | >99% | RSABE |
| Cmax | 1.08 | 0.696 (0.655; 0.744) | 1.10 | 0.700 | 96% | RSABE |

ABE = average bioequivalence; NMPA = National Medical Products Administration; Ref = reference; SDw = within-subject standard deviation; RSABE = Reference-scaled average bioequivalence approach.

Reference-scaled average bioequivalence approach was used according to NMPA guidance for bioequivalence study for highly variable drugs.